FDA grants orphan drug status to Merck's pembrolizumab for neuroendocrine prostate cancer

se.investing.com (Swedish)

The FDA granted orphan drug status to Merck's pembrolizumab for neuroendocrine prostate cancer. This designation, given on June 6, 2026, provides incentives for developing treatments for rare diseases affecting fewer than 200,000 people in the U.S. Pembrolizumab, marketed as Keytruda, is currently being investigated in clinical trials for this indication, typically for patients with advanced or metastatic disease.


With a significance score of 2.3, this news ranks in the top 21% of today's 33682 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


FDA grants orphan drug status to Merck's pembrolizumab for neuroendocrine prostate cancer | News Minimalist